<DOC>
	<DOCNO>NCT00789477</DOCNO>
	<brief_summary>This Phase 2 , doubled-masked , randomize study efficacy safety Intravitreal Aflibercept Injection ( IAI ; EYLEA® ; BAY86-5321 ) subject diabetic macular edema ( DME ) . Approximately 200 subject randomize US , Canada , Australia EU .</brief_summary>
	<brief_title>DME And VEGF Trap-Eye Intravitreal Aflibercept Injection ( IAI ; EYLEA® ; BAY86-5321 ) INvestigation Clinical Impact</brief_title>
	<detailed_description>Qualified subject randomize one 5 treatment arm . The active ( treatment ) phase study 52 week , 6 month safety follow-up</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<criteria>Patients clinically significant DME central involvement Adults 18 year old type 1 2 diabetes mellitus diabetic macular edema ETDRS BCVA : 20/40 20/320 ( letter score 73 24 ) study eye History vitreoretinal surgery study eye Panretinal laser photocoagulation macular laser photocoagulation study eye within 3 month screen Previous use intraocular periocular corticosteroid study eye within 3 month screen Previous treatment antiangiogenic drug either eye ( pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , etc ) within 3 month screen Uncontrolled diabetes mellitus Uncontrolled hypertension define systolic &gt; 180mmHg &gt; 160 mmHg 2 consecutive measurement diastolic &gt; 100 mmHg optimal medical regimen Ocular disorder study eye , DME , may confound interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>